News AbbVie Inc.

Equities

ABBV

US00287Y1091

Pharmaceuticals

Market Closed - Nyse Other stock markets 00:02:10 22/04/2026 +04			5-day change	1st Jan Change
205.12 ^USD	+0.69%		-2.44%	-10.23%

04-21	Correction to AbbVie Article on April 20	DJ
04-21	Canaccord Genuity Initiates AbbVie at Buy With $262 Price Target	MT

All News

04-21	Correction to AbbVie Article on April 20	DJ
04-21	Canaccord Genuity Initiates AbbVie at Buy With $262 Price Target	MT
04-20	AbbVie Sponsors New BioLabs Facility in Toronto	DJ
04-20	AbbVie and Biolabs team up to support Life Sciences Innovation in Canada	RE
04-20	AbbVie and BioLabs Team Up to Support Life Sciences Innovation in Canada	AQ
04-20	Amazon's collusion drove up consumer prices, California says, citing new evidence	RE
04-20	Ruled by Headlines
04-20	Nxera Pharma Co., Ltd. Reaches Third R&D Milestone Under Collaboration with Abbvie	CI
04-20	Nxera Pharma to Receive $10 Million Milestone from AbbVie for Neurology Collaboration	MT
04-20	AbbVie Makes $10 Million Milestone Payment to Nxera Pharma Under Collaboration	MT
04-20	Nxera Pharma Co Ltd - to receive US$10 million milestone payment from AbbVie under collaboration targeting neurological diseases	RE
04-16	Helus Pharma Appoints Dr. Ken Kramer as Senior Vice President, Medical Affairs, Effective April 16, 2026	CI
04-15	Johnson & Johnson Reported Above-Peer Topline Growth in Q1, BofA Says	MT
04-15	RemeGen Receives $650 Million Upfront Payment From AbbVie Under Licensing Agreement	MT
04-15	RemeGen Co., Ltd. and Abbvie Enter Exclusive License Agreement for RC148 with USD 650 Million Upfront Payment	CI
04-15		FA
04-14	Erin Lichy Gets Real About Her Natrelle® Breast Augmentation	PR
04-13	Evercore ISI Adjusts AbbVie Price Target to $232 From $233, Maintains Outperform Rating	MT
04-13	Earnings Season in Trump's Shadow
04-13	CollPlant Biotechnologies Ltd and Allergan Industrie SAS Terminate Development Agreement	CI
04-13	AbbVie Showcases Late-Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE) in Platinum-Sensitive Ovarian Cancer (PSOC) at SGO 2026	AQ
04-13	Haisco Pharmaceutical Group Co., Ltd. Enters Exclusive License Agreement with AbbVie	CI
04-13	Chinese Stocks Muted Amid Failed US-Iran Talks, Improved GDP Outlook	MT
04-13	AbbVie Signs Global Pain Drug Licensing Deal With Haisco	MT
04-12	AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026	PR